Products and
Pipeline

Important Information About EXKIVITY^® (mobocertinib)

On October 2, 2023, Takeda announced the initiation of a voluntary withdrawal of EXKIVITY (mobocertinib) 40 mg capsules, for oral use, from the market in the United States (U.S.). This decision was made in consultation with the US Food and Drug Administration (FDA).

EXKIVITY is not being withdrawn immediately and we want to emphasize Takeda’s commitment to ensuring patients who are currently receiving EXKIVITY can maintain access as appropriate and in consultation with their healthcare provider. Patients currently on treatment should consult with their healthcare provider for more information. Takeda will be following up with prescribers and patients with updates when and as appropriate to keep you informed. Updates will also be available at www.exkivity-update.com.

For additional questions please contact Takeda at 844-662-8532 or globaloncologymedinfo@takeda.com.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals America, Inc. at
1-844-217-6468 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Iclusig (Ponatinib)

ICLUSIG^® (ponatinib) is now indicated for the treatment of adult patients with:

• Chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors.
• Accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated.
• T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL.

Limitations of Use: Iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.